Manuscript Discussing The Benefit Of SeaStar Medical's Selective Cytopheretic Device In Patients With Heart Failure And Hyperinflammation Published In European Journal Of Heart Failure
Manuscript Discussing The Benefit Of SeaStar Medical's Selective Cytopheretic Device In Patients With Heart Failure And Hyperinflammation Published In European Journal Of Heart Failure
《欧洲心力衰竭杂志》上发表的关于SeaStar Medical选择性细胞移植设备对心力衰竭和炎症过度患者的益处的手稿
Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients
人们对制定减少全身性炎症的新策略的兴趣持续增长，以此作为改善心力衰竭患者预后的一种手段
DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces publication of a manuscript discussing the role of chronic dysregulated systemic inflammation in heart failure and the potential application of the adult Selective Cytopheretic Device, part of the Quelimmune product family, in enabling previously ineligible patients with severe disease to receive a left ventricular assist device (LVAD) or heart transplant in...
丹佛，2024年2月27日（GLOBE NEWSWIRE）——开发专有解决方案以减少重要器官炎症后果的医疗器械公司SeaStar Medical Holdi...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。